Pim-1 kinase expression predicts radiation response in squamocellular carcinoma of head and neck and is under the control of epidermal growth factor receptor

Neoplasia

Volumn 11, Issue 7, 2009, Pages 629-636

  Peltola, Katriina ^a   Hollmen, Maija ^a,b   Maula, Sanna Mari ^a,b   Rainio, Eeva ^a   Ristamäki, Raija ^c   Luukkaa, Marjaana ^c   Sandholm, Jouko ^a   Sundvall, Maria ^a,b   Elenius, Klaus ^a,b,c   Koskinen, Päivi J ^a   Grenman, Reidar ^a,c   Jalkanen, Sirpa ^a,b  

^a UNIVERSITY OF TURKU   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; PROTEIN KINASE PIM 1; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR ALPHA;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER RADIOTHERAPY; CELL SURVIVAL; CONTROLLED STUDY; FEMALE; HEAD AND NECK CARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; RADIATION RESPONSE; RADIOSENSITIVITY; SQUAMOUS CELL CARCINOMA; UPREGULATION;

EID: 67650498487     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.81038     Document Type: Article

References (35)

1. Lilly M, Sandholm J, Cooper JJ, Koskinen PJ, and Kraft A (1999). The PIM-1 serine kinase prolongs survival and inhibits apoptosis-related mitochondrial dysfunction in part through a bcl-2-dependent pathway. Oncogene 18, 4022-4031.
2. Lilly Mand Kraft A (1997). Enforced expression of the Mr 33,000 Pim-1 kinase enhances factor-independent survival and inhibits apoptosis in murine myeloid cells. Cancer Res 57, 5348-5355.
3. Leverson JD, Koskinen PJ, Orrico FC, Rainio EM, Jalkanen KJ, Dash AB, Eisenman RN, and Ness SA (1998). Pim-1 kinase and p100 cooperate to enhance c-Myb activity. Mol Cell 2, 417-425.
4. Rainio EM, Sandholm J, and Koskinen PJ (2002). Cutting edge: transcriptional activity of NFATc1 is enhanced by the Pim-1 kinase. J Immunol 168, 1524-1527.
5. Mochizuki T, Kitanaka C, Noguchi K, Muramatsu T, Asai A, and Kuchino Y (1999). Physical and functional interactions between Pim-1 kinase and Cdc25A phosphatase. Implications for the Pim-1-mediated activation of the c-Myc signaling pathway. J Biol Chem 274, 18659-18666.
6. Cip1/WAF1 by Pim-1 kinase. Biochim Biophys Acta 1593, 45-55.
7. Bhattacharya N, Wang Z, Davitt C, McKenzie IF, Xing PX, and Magnuson NS (2002). Pim-1 associates with protein complexes necessary for mitosis. Chromosoma 111, 80-95.
8. Bachmann M and Moroy T (2005). The serine/threonine kinase Pim-1. Int J Biochem Cell Biol 37, 726-730.
9. Cuypers HT, Selten G, Quint W, Zijlstra M, Maandag ER, Boelens W, van Wezenbeek P, Melief C, and Berns A (1984). Murine leukemia virus-induced T-cell lymphomagenesis: integration of proviruses in a distinct chromosomal region. Cell 37, 141-150.
10. van Lohuizen M, Verbeek S, Krimpenfort P, Domen J, Saris C, Radaszkiewicz T, and Berns A (1989). Predisposition to lymphomagenesis in pim-1 transgenic mice: cooperation with c-myc and N-myc in murine leukemia virus-induced tumors. Cell 56, 673-682.
11. Möröy T, Verbeek S, Ma A, Achacoso P, Berns A, and Alt F (1991). Eμ N- and Eμ L-myc cooperate with E mu pim-1 to generate lymphoid tumors at high frequency in double-transgenic mice. Oncogene 6, 1941-1948.
12. Acton D, Domen J, Jacobs H, Vlaar M, Korsmeyer S, and Berns A (1992). Collaboration of pim-1 and bcl-2 in lymphomagenesis. Curr Top Microbiol Immunol 182, 293-298.
13. Schmidt T, Karsunky H, Gau E, Zevnik B, Elsasser HP, and Moroy T (1998). Zinc finger protein GFI-1 has low oncogenic potential but cooperates strongly with pim and myc genes in T-cell lymphomagenesis. Oncogene 17, 2661-2667.
14. pim is expressed during fetal hematopoiesis and in diverse leukemias. Proc Natl Acad Sci USA 86, 8857-8861.
15. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, and Chinnaiyan AM (2001). Delineation of prognostic biomarkers in prostate cancer. Nature 412, 822-826.
16. Maula SM, Luukkaa M, Grenman R, Jackson D, Jalkanen S, and Ristamäki R (2003). Intratumoral lymphatics are essential for the metastatic spread and prognosis in squamous cell carcinomas of the head and neck region. Cancer Res 63, 1920-1926.
17. Boukamp P, Petrussevska RT, Breitkreutz D, Hornung J, Markham A, and Fusenig NE (1988). Normal keratinization in a spontaneously immortalized aneuploid keratinocyte cell line. J Cell Biol 106, 761-771.
18. Grenman R, Pekkola-Heino K, Joensuu H, Aitasalo K, Klemi P, and Lakkala T (1992). UT-MUC-1, a new mucoepidermoid carcinoma cell line, and its radio-sensitivity. Arch Otolaryngol Head Neck Surg 118, 542-547.
19. Chen DJ and Nirodi CS (2007). The epidermal growth factor receptor: a role in repair of radiation-induced DNA damage. Clin Cancer Res 13, 6555-6560.
20. Akimoto T, Hunter NR, Buchmiller L, Mason K, Ang KK, and Milas L (1999). Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res 5, 2884-2890.
21. Ionov Y, Le X, Tunquist BJ, Sweetenham J, Sachs T, Ryder J, Johnson T, Lilly MB, and Kraft AS (2003). Pim-1 protein kinase is nuclear in Burkitt's lymphoma: nuclear localization is necessary for its biologic effects. Anticancer Res 23, 167-178.
22. Zwang Y and Yarden Y (2006). p38 MAP kinase mediates stress-induced internalization of EGFR: implications for cancer chemotherapy. EMBO J 25, 4195-4206.
23. Roh M, Gary B, Song C, Said-Al-Naief N, Tousson A, Kraft A, Eltoum IE, and Abdulkadir SA (2003). Overexpression of the oncogenic kinase Pim-1 leads to genomic instability. Cancer Res 63, 8079-8084.
24. Pircher TJ, Zhao S, Geiger JN, Joneja B, and Wojchowski DM (2000). Pim-1 kinase protects hematopoietic FDC cells from genotoxin-induced death. Oncogene 19, 3684-3692.
25. van der Houven van OordtCW, Schouten TG, van Krieken JH, van Dierendonck JH, van der Eb AJ, and Breuer ML (1998). x-Ray-induced lymphomagenesis in E mu-pim-1 transgenic mice: an investigation of the co-operating molecular events. Carcinogenesis 19, 847-853.
26. Chiang WF, Yen CY, Lin CN, Liaw GA, Chiu CT, Hsia YJ, and Liu SY (2006). Up-regulation of a serine-threonine kinase proto-oncogene Pim-1 in oral squamous cell carcinoma. Int J Oral Maxillofac Surg 35, 740-745.
27. Peltola KJ, Paukku K, Aho TL, Ruuska M, Silvennoinen O, and Koskinen PJ (2004). Pim-1 kinase inhibits STAT5-dependent transcription via its interactions with SOCS1 and SOCS3. Blood 103, 3744-3750.
28. Qian KC, Wang L, Hickey ER, Studts J, Barringer K, Peng C, Kronkaitis A, Li J, White A,Mische S, et al. (2005). Structural basis of constitutive activity and a unique nucleotide binding mode of human Pim-1 kinase. J Biol Chem 280, 6130-6137.
29. Song JI and Grandis JR (2000). STAT signaling in head and neck cancer. Oncogene 19, 2489-2495.
30. Quesnelle KM, Boehm AL, and Grandis JR (2007). STAT-mediated EGFR signaling in cancer. J Cell Biochem 102, 311-319.
31. Erjala K, Sundvall M, Junttila TT, Zhang N, Savisalo M, Mali P, Kulmala J, Pulkkinen J, Grenman R, and Elenius K (2006). Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Clin Cancer Res 12, 4103-4111.
32. Caponigro F, Formato R, Caraglia M, Normanno N, and Iaffaioli RV (2005). Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors. Curr Opin Oncol 17, 212-217.
33. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, et al. (2006). Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354, 567-578.
34. Holder S, Zemskova M, Zhang C, Tabrizizad M, Bremer R, Neidigh JW, and Lilly MB (2007). Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase. Mol Cancer Ther 6, 163-172.
35. Zemskova M, Sahakian E, Bashkirova S, and Lilly M (2008). The PIM1 kinase is a critical component of a survival pathway activated by docetaxel and promotes survival of docetaxel-treated prostate cancer cells. J Biol Chem 283, 20635-20644.